HEALTHSTAT NEWS
STAT+: Five biotech news updates to stay on top of today
Eli Lilly’s gene-editing data shows promise for treating high cholesterol, an AI drug discovery CEO addressed industry hype, and the new interim FDA chief has received positive initial reactions. The article highlights key biotech developments impacting science and regulatory landscapes.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Pharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
- STAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study
- STAT+: AstraZeneca picks up FDA approval for hypertension drug
- Guarding biotech from China and big bets in longevity
- STAT+: OpenAI’s health policy wishlist, CGM news from Dexcom, and more
- STAT+: Even at a meeting in Rome, FDA shifts are top of mind for gene therapy field